nodes	percent_of_prediction	percent_of_DWPC	metapath
Etonogestrel—PGR—Nuclear Receptors—THRB—thyroid cancer	0.0121	0.067	CbGpPWpGaD
Etonogestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.0111	0.0613	CbGpPWpGaD
Etonogestrel—PGR—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00955	0.0529	CbGpPWpGaD
Etonogestrel—ESR1—Nuclear Receptors—THRB—thyroid cancer	0.0071	0.0393	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.00707	0.0392	CbGpPWpGaD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00655	0.0363	CbGpPWpGaD
Etonogestrel—ESR1—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00561	0.0311	CbGpPWpGaD
Etonogestrel—PGR—Nuclear Receptors—RXRA—thyroid cancer	0.00514	0.0285	CbGpPWpGaD
Etonogestrel—PGR—Nuclear signaling by ERBB4—NRG1—thyroid cancer	0.00435	0.0241	CbGpPWpGaD
Etonogestrel—SHBG—Nongenotropic Androgen signaling—HRAS—thyroid cancer	0.00421	0.0233	CbGpPWpGaD
Etonogestrel—PGR—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00406	0.0225	CbGpPWpGaD
Etonogestrel—SHBG—Nongenotropic Androgen signaling—AKT1—thyroid cancer	0.00371	0.0206	CbGpPWpGaD
Etonogestrel—PGR—Nuclear Receptors—PPARG—thyroid cancer	0.00324	0.018	CbGpPWpGaD
Etonogestrel—ESR1—Nuclear Receptors—RXRA—thyroid cancer	0.00301	0.0167	CbGpPWpGaD
Etonogestrel—ESR1—FOXM1 transcription factor network—CDK1—thyroid cancer	0.003	0.0166	CbGpPWpGaD
Etonogestrel—Erythema—Sorafenib—thyroid cancer	0.00293	0.00357	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Vandetanib—thyroid cancer	0.0029	0.00353	CcSEcCtD
Etonogestrel—Abscess—Doxorubicin—thyroid cancer	0.00289	0.00353	CcSEcCtD
Etonogestrel—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00286	0.0158	CbGpPWpGaD
Etonogestrel—Breast pain—Epirubicin—thyroid cancer	0.00284	0.00346	CcSEcCtD
Etonogestrel—Amenorrhoea—Epirubicin—thyroid cancer	0.00282	0.00344	CcSEcCtD
Etonogestrel—Muscle spasms—Sorafenib—thyroid cancer	0.00281	0.00343	CcSEcCtD
Etonogestrel—Injection site pain—Doxorubicin—thyroid cancer	0.00281	0.00342	CcSEcCtD
Etonogestrel—Abdominal pain—Vandetanib—thyroid cancer	0.0028	0.00342	CcSEcCtD
Etonogestrel—Body temperature increased—Vandetanib—thyroid cancer	0.0028	0.00342	CcSEcCtD
Etonogestrel—ESR1—Estrogen signaling pathway—BRAF—thyroid cancer	0.00277	0.0153	CbGpPWpGaD
Etonogestrel—Herpes simplex—Epirubicin—thyroid cancer	0.00269	0.00328	CcSEcCtD
Etonogestrel—Angioedema—Sorafenib—thyroid cancer	0.00268	0.00326	CcSEcCtD
Etonogestrel—Breast pain—Doxorubicin—thyroid cancer	0.00262	0.0032	CcSEcCtD
Etonogestrel—Amenorrhoea—Doxorubicin—thyroid cancer	0.00261	0.00318	CcSEcCtD
Etonogestrel—Bone pain—Epirubicin—thyroid cancer	0.00258	0.00315	CcSEcCtD
Etonogestrel—PGR—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.00256	0.0142	CbGpPWpGaD
Etonogestrel—Cough—Sorafenib—thyroid cancer	0.00255	0.00312	CcSEcCtD
Etonogestrel—ESR1—Nuclear signaling by ERBB4—NRG1—thyroid cancer	0.00255	0.0141	CbGpPWpGaD
Etonogestrel—Asthenia—Vandetanib—thyroid cancer	0.00254	0.0031	CcSEcCtD
Etonogestrel—Hypertension—Sorafenib—thyroid cancer	0.00253	0.00308	CcSEcCtD
Etonogestrel—Pruritus—Vandetanib—thyroid cancer	0.00251	0.00306	CcSEcCtD
Etonogestrel—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00251	0.00306	CcSEcCtD
Etonogestrel—Myalgia—Sorafenib—thyroid cancer	0.00249	0.00304	CcSEcCtD
Etonogestrel—Arthralgia—Sorafenib—thyroid cancer	0.00249	0.00304	CcSEcCtD
Etonogestrel—Herpes simplex—Doxorubicin—thyroid cancer	0.00249	0.00303	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00248	0.00302	CcSEcCtD
Etonogestrel—Vaginal inflammation—Epirubicin—thyroid cancer	0.00248	0.00302	CcSEcCtD
Etonogestrel—Hepatocellular injury—Epirubicin—thyroid cancer	0.00248	0.00302	CcSEcCtD
Etonogestrel—Injection site reaction—Epirubicin—thyroid cancer	0.00246	0.003	CcSEcCtD
Etonogestrel—Diarrhoea—Vandetanib—thyroid cancer	0.00242	0.00296	CcSEcCtD
Etonogestrel—Cystitis noninfective—Epirubicin—thyroid cancer	0.00242	0.00295	CcSEcCtD
Etonogestrel—Influenza like illness—Epirubicin—thyroid cancer	0.0024	0.00293	CcSEcCtD
Etonogestrel—Bone pain—Doxorubicin—thyroid cancer	0.00239	0.00292	CcSEcCtD
Etonogestrel—Cystitis—Epirubicin—thyroid cancer	0.00239	0.00292	CcSEcCtD
Etonogestrel—Anaphylactic shock—Sorafenib—thyroid cancer	0.00239	0.00292	CcSEcCtD
Etonogestrel—ESR1—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00238	0.0132	CbGpPWpGaD
Etonogestrel—Infection—Sorafenib—thyroid cancer	0.00237	0.0029	CcSEcCtD
Etonogestrel—Fluid retention—Epirubicin—thyroid cancer	0.00235	0.00287	CcSEcCtD
Etonogestrel—Nervous system disorder—Sorafenib—thyroid cancer	0.00234	0.00286	CcSEcCtD
Etonogestrel—Dizziness—Vandetanib—thyroid cancer	0.00234	0.00286	CcSEcCtD
Etonogestrel—Vaginal infection—Epirubicin—thyroid cancer	0.00234	0.00285	CcSEcCtD
Etonogestrel—Skin disorder—Sorafenib—thyroid cancer	0.00232	0.00283	CcSEcCtD
Etonogestrel—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00232	0.00283	CcSEcCtD
Etonogestrel—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00229	0.00279	CcSEcCtD
Etonogestrel—Vaginal inflammation—Doxorubicin—thyroid cancer	0.00229	0.00279	CcSEcCtD
Etonogestrel—PGR—Generic Transcription Pathway—TRIM33—thyroid cancer	0.00228	0.0126	CbGpPWpGaD
Etonogestrel—Anorexia—Sorafenib—thyroid cancer	0.00228	0.00278	CcSEcCtD
Etonogestrel—Injection site reaction—Doxorubicin—thyroid cancer	0.00228	0.00278	CcSEcCtD
Etonogestrel—Vomiting—Vandetanib—thyroid cancer	0.00225	0.00275	CcSEcCtD
Etonogestrel—Bladder pain—Epirubicin—thyroid cancer	0.00224	0.00273	CcSEcCtD
Etonogestrel—Neoplasm—Epirubicin—thyroid cancer	0.00224	0.00273	CcSEcCtD
Etonogestrel—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00224	0.00273	CcSEcCtD
Etonogestrel—Rash—Vandetanib—thyroid cancer	0.00223	0.00273	CcSEcCtD
Etonogestrel—Dermatitis—Vandetanib—thyroid cancer	0.00223	0.00272	CcSEcCtD
Etonogestrel—Influenza like illness—Doxorubicin—thyroid cancer	0.00222	0.00271	CcSEcCtD
Etonogestrel—Headache—Vandetanib—thyroid cancer	0.00222	0.00271	CcSEcCtD
Etonogestrel—Cystitis—Doxorubicin—thyroid cancer	0.00221	0.0027	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00218	0.00266	CcSEcCtD
Etonogestrel—Fluid retention—Doxorubicin—thyroid cancer	0.00217	0.00265	CcSEcCtD
Etonogestrel—Vaginal infection—Doxorubicin—thyroid cancer	0.00216	0.00264	CcSEcCtD
Etonogestrel—Abnormal vision—Epirubicin—thyroid cancer	0.00216	0.00263	CcSEcCtD
Etonogestrel—Nausea—Vandetanib—thyroid cancer	0.0021	0.00257	CcSEcCtD
Etonogestrel—Dyspepsia—Sorafenib—thyroid cancer	0.0021	0.00257	CcSEcCtD
Etonogestrel—Decreased appetite—Sorafenib—thyroid cancer	0.00208	0.00253	CcSEcCtD
Etonogestrel—Neoplasm—Doxorubicin—thyroid cancer	0.00207	0.00253	CcSEcCtD
Etonogestrel—Bladder pain—Doxorubicin—thyroid cancer	0.00207	0.00253	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00206	0.00252	CcSEcCtD
Etonogestrel—Fatigue—Sorafenib—thyroid cancer	0.00206	0.00251	CcSEcCtD
Etonogestrel—Constipation—Sorafenib—thyroid cancer	0.00204	0.00249	CcSEcCtD
Etonogestrel—Pain—Sorafenib—thyroid cancer	0.00204	0.00249	CcSEcCtD
Etonogestrel—Eczema—Epirubicin—thyroid cancer	0.002	0.00244	CcSEcCtD
Etonogestrel—Abnormal vision—Doxorubicin—thyroid cancer	0.002	0.00244	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—CDK1—thyroid cancer	0.00199	0.011	CbGpPWpGaD
Etonogestrel—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00195	0.00238	CcSEcCtD
Etonogestrel—Hot flush—Epirubicin—thyroid cancer	0.00192	0.00234	CcSEcCtD
Etonogestrel—Increased appetite—Epirubicin—thyroid cancer	0.00191	0.00233	CcSEcCtD
Etonogestrel—Menopausal symptoms—Epirubicin—thyroid cancer	0.0019	0.00232	CcSEcCtD
Etonogestrel—ESR1—Nuclear Receptors—PPARG—thyroid cancer	0.0019	0.0105	CbGpPWpGaD
Etonogestrel—Urticaria—Sorafenib—thyroid cancer	0.0019	0.00232	CcSEcCtD
Etonogestrel—Body temperature increased—Sorafenib—thyroid cancer	0.00189	0.0023	CcSEcCtD
Etonogestrel—Abdominal pain—Sorafenib—thyroid cancer	0.00189	0.0023	CcSEcCtD
Etonogestrel—Eczema—Doxorubicin—thyroid cancer	0.00185	0.00226	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—CDK1—thyroid cancer	0.00183	0.0101	CbGpPWpGaD
Etonogestrel—Pain in extremity—Epirubicin—thyroid cancer	0.0018	0.00219	CcSEcCtD
Etonogestrel—Hot flush—Doxorubicin—thyroid cancer	0.00178	0.00217	CcSEcCtD
Etonogestrel—Increased appetite—Doxorubicin—thyroid cancer	0.00177	0.00216	CcSEcCtD
Etonogestrel—Affect lability—Epirubicin—thyroid cancer	0.00177	0.00216	CcSEcCtD
Etonogestrel—Migraine—Epirubicin—thyroid cancer	0.00177	0.00216	CcSEcCtD
Etonogestrel—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00176	0.00215	CcSEcCtD
Etonogestrel—Hypersensitivity—Sorafenib—thyroid cancer	0.00176	0.00215	CcSEcCtD
Etonogestrel—Asthenia—Sorafenib—thyroid cancer	0.00171	0.00209	CcSEcCtD
Etonogestrel—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00171	0.00948	CbGpPWpGaD
Etonogestrel—Mood swings—Epirubicin—thyroid cancer	0.0017	0.00208	CcSEcCtD
Etonogestrel—Pruritus—Sorafenib—thyroid cancer	0.00169	0.00206	CcSEcCtD
Etonogestrel—Pain in extremity—Doxorubicin—thyroid cancer	0.00166	0.00203	CcSEcCtD
Etonogestrel—PGR—Generic Transcription Pathway—THRB—thyroid cancer	0.00165	0.00914	CbGpPWpGaD
Etonogestrel—Affect lability—Doxorubicin—thyroid cancer	0.00164	0.002	CcSEcCtD
Etonogestrel—Migraine—Doxorubicin—thyroid cancer	0.00164	0.002	CcSEcCtD
Etonogestrel—Diarrhoea—Sorafenib—thyroid cancer	0.00163	0.00199	CcSEcCtD
Etonogestrel—Breast disorder—Epirubicin—thyroid cancer	0.00162	0.00198	CcSEcCtD
Etonogestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—thyroid cancer	0.0016	0.00886	CbGpPWpGaD
Etonogestrel—Gastritis—Epirubicin—thyroid cancer	0.00159	0.00194	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.00159	0.00881	CbGpPWpGaD
Etonogestrel—Dizziness—Sorafenib—thyroid cancer	0.00158	0.00193	CcSEcCtD
Etonogestrel—Mood swings—Doxorubicin—thyroid cancer	0.00157	0.00192	CcSEcCtD
Etonogestrel—Abdominal distension—Epirubicin—thyroid cancer	0.00156	0.00191	CcSEcCtD
Etonogestrel—Asthma—Epirubicin—thyroid cancer	0.00155	0.00189	CcSEcCtD
Etonogestrel—Vomiting—Sorafenib—thyroid cancer	0.00152	0.00185	CcSEcCtD
Etonogestrel—PGR—Validated nuclear estrogen receptor alpha network—CCND1—thyroid cancer	0.00152	0.00842	CbGpPWpGaD
Etonogestrel—Rash—Sorafenib—thyroid cancer	0.00151	0.00184	CcSEcCtD
Etonogestrel—Dermatitis—Sorafenib—thyroid cancer	0.00151	0.00184	CcSEcCtD
Etonogestrel—ESR1—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.0015	0.00833	CbGpPWpGaD
Etonogestrel—Breast disorder—Doxorubicin—thyroid cancer	0.0015	0.00183	CcSEcCtD
Etonogestrel—Headache—Sorafenib—thyroid cancer	0.0015	0.00183	CcSEcCtD
Etonogestrel—Bronchitis—Epirubicin—thyroid cancer	0.00149	0.00182	CcSEcCtD
Etonogestrel—Gastritis—Doxorubicin—thyroid cancer	0.00147	0.0018	CcSEcCtD
Etonogestrel—ESR1—Regulation of Telomerase—TERT—thyroid cancer	0.00147	0.00814	CbGpPWpGaD
Etonogestrel—PGR—Signaling by ERBB4—NRG1—thyroid cancer	0.00147	0.00812	CbGpPWpGaD
Etonogestrel—Dysuria—Epirubicin—thyroid cancer	0.00145	0.00177	CcSEcCtD
Etonogestrel—Abdominal distension—Doxorubicin—thyroid cancer	0.00145	0.00177	CcSEcCtD
Etonogestrel—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00144	0.00176	CcSEcCtD
Etonogestrel—Asthma—Doxorubicin—thyroid cancer	0.00144	0.00175	CcSEcCtD
Etonogestrel—Pollakiuria—Epirubicin—thyroid cancer	0.00143	0.00175	CcSEcCtD
Etonogestrel—Nausea—Sorafenib—thyroid cancer	0.00142	0.00173	CcSEcCtD
Etonogestrel—Weight increased—Epirubicin—thyroid cancer	0.00141	0.00172	CcSEcCtD
Etonogestrel—Weight decreased—Epirubicin—thyroid cancer	0.0014	0.00171	CcSEcCtD
Etonogestrel—Infestation NOS—Epirubicin—thyroid cancer	0.00138	0.00169	CcSEcCtD
Etonogestrel—Infestation—Epirubicin—thyroid cancer	0.00138	0.00169	CcSEcCtD
Etonogestrel—Bronchitis—Doxorubicin—thyroid cancer	0.00138	0.00169	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—HIF1A—thyroid cancer	0.00137	0.00761	CbGpPWpGaD
Etonogestrel—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00136	0.00166	CcSEcCtD
Etonogestrel—Urinary tract infection—Epirubicin—thyroid cancer	0.00135	0.00164	CcSEcCtD
Etonogestrel—Dysuria—Doxorubicin—thyroid cancer	0.00134	0.00164	CcSEcCtD
Etonogestrel—ESR1—Generic Transcription Pathway—TRIM33—thyroid cancer	0.00134	0.00742	CbGpPWpGaD
Etonogestrel—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00134	0.00163	CcSEcCtD
Etonogestrel—Pollakiuria—Doxorubicin—thyroid cancer	0.00133	0.00162	CcSEcCtD
Etonogestrel—Weight increased—Doxorubicin—thyroid cancer	0.00131	0.0016	CcSEcCtD
Etonogestrel—Weight decreased—Doxorubicin—thyroid cancer	0.0013	0.00159	CcSEcCtD
Etonogestrel—Sinusitis—Epirubicin—thyroid cancer	0.0013	0.00159	CcSEcCtD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.00129	0.00712	CbGpPWpGaD
Etonogestrel—Infestation NOS—Doxorubicin—thyroid cancer	0.00128	0.00156	CcSEcCtD
Etonogestrel—Infestation—Doxorubicin—thyroid cancer	0.00128	0.00156	CcSEcCtD
Etonogestrel—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00126	0.00153	CcSEcCtD
Etonogestrel—Haemoglobin—Epirubicin—thyroid cancer	0.00125	0.00152	CcSEcCtD
Etonogestrel—ESR1—FOXM1 transcription factor network—CCND1—thyroid cancer	0.00125	0.00692	CbGpPWpGaD
Etonogestrel—Rhinitis—Epirubicin—thyroid cancer	0.00125	0.00152	CcSEcCtD
Etonogestrel—Urinary tract infection—Doxorubicin—thyroid cancer	0.00125	0.00152	CcSEcCtD
Etonogestrel—Haemorrhage—Epirubicin—thyroid cancer	0.00124	0.00152	CcSEcCtD
Etonogestrel—Hypoaesthesia—Epirubicin—thyroid cancer	0.00124	0.00151	CcSEcCtD
Etonogestrel—Pharyngitis—Epirubicin—thyroid cancer	0.00123	0.00151	CcSEcCtD
Etonogestrel—Urinary tract disorder—Epirubicin—thyroid cancer	0.00123	0.0015	CcSEcCtD
Etonogestrel—Connective tissue disorder—Epirubicin—thyroid cancer	0.00122	0.00149	CcSEcCtD
Etonogestrel—Urethral disorder—Epirubicin—thyroid cancer	0.00122	0.00149	CcSEcCtD
Etonogestrel—Sinusitis—Doxorubicin—thyroid cancer	0.0012	0.00147	CcSEcCtD
Etonogestrel—Visual impairment—Epirubicin—thyroid cancer	0.0012	0.00146	CcSEcCtD
Etonogestrel—Eye disorder—Epirubicin—thyroid cancer	0.00116	0.00142	CcSEcCtD
Etonogestrel—Haemoglobin—Doxorubicin—thyroid cancer	0.00116	0.00141	CcSEcCtD
Etonogestrel—Rhinitis—Doxorubicin—thyroid cancer	0.00115	0.00141	CcSEcCtD
Etonogestrel—Haemorrhage—Doxorubicin—thyroid cancer	0.00115	0.0014	CcSEcCtD
Etonogestrel—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00114	0.0014	CcSEcCtD
Etonogestrel—Pharyngitis—Doxorubicin—thyroid cancer	0.00114	0.00139	CcSEcCtD
Etonogestrel—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00114	0.00139	CcSEcCtD
Etonogestrel—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00113	0.00138	CcSEcCtD
Etonogestrel—Angiopathy—Epirubicin—thyroid cancer	0.00113	0.00138	CcSEcCtD
Etonogestrel—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00113	0.00625	CbGpPWpGaD
Etonogestrel—Urethral disorder—Doxorubicin—thyroid cancer	0.00113	0.00138	CcSEcCtD
Etonogestrel—ESR1—Estrogen signaling pathway—AKT1—thyroid cancer	0.00112	0.00623	CbGpPWpGaD
Etonogestrel—Immune system disorder—Epirubicin—thyroid cancer	0.00112	0.00137	CcSEcCtD
Etonogestrel—Visual impairment—Doxorubicin—thyroid cancer	0.00111	0.00135	CcSEcCtD
Etonogestrel—PGR—Gene Expression—TRIM33—thyroid cancer	0.0011	0.00609	CbGpPWpGaD
Etonogestrel—Alopecia—Epirubicin—thyroid cancer	0.0011	0.00134	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—NRAS—thyroid cancer	0.0011	0.00607	CbGpPWpGaD
Etonogestrel—Mental disorder—Epirubicin—thyroid cancer	0.00109	0.00133	CcSEcCtD
Etonogestrel—Erythema—Epirubicin—thyroid cancer	0.00108	0.00132	CcSEcCtD
Etonogestrel—Malnutrition—Epirubicin—thyroid cancer	0.00108	0.00132	CcSEcCtD
Etonogestrel—Eye disorder—Doxorubicin—thyroid cancer	0.00107	0.00131	CcSEcCtD
Etonogestrel—ESR1—Signaling by ERBB4—CDK1—thyroid cancer	0.00107	0.00594	CbGpPWpGaD
Etonogestrel—Flatulence—Epirubicin—thyroid cancer	0.00107	0.0013	CcSEcCtD
Etonogestrel—Tension—Epirubicin—thyroid cancer	0.00106	0.0013	CcSEcCtD
Etonogestrel—Nervousness—Epirubicin—thyroid cancer	0.00105	0.00128	CcSEcCtD
Etonogestrel—PGR—Generic Transcription Pathway—MEN1—thyroid cancer	0.00105	0.00581	CbGpPWpGaD
Etonogestrel—Back pain—Epirubicin—thyroid cancer	0.00105	0.00128	CcSEcCtD
Etonogestrel—Angiopathy—Doxorubicin—thyroid cancer	0.00104	0.00127	CcSEcCtD
Etonogestrel—Muscle spasms—Epirubicin—thyroid cancer	0.00104	0.00127	CcSEcCtD
Etonogestrel—Immune system disorder—Doxorubicin—thyroid cancer	0.00104	0.00127	CcSEcCtD
Etonogestrel—Alopecia—Doxorubicin—thyroid cancer	0.00102	0.00124	CcSEcCtD
Etonogestrel—Mental disorder—Doxorubicin—thyroid cancer	0.00101	0.00123	CcSEcCtD
Etonogestrel—Ill-defined disorder—Epirubicin—thyroid cancer	0.001	0.00123	CcSEcCtD
Etonogestrel—Erythema—Doxorubicin—thyroid cancer	0.001	0.00122	CcSEcCtD
Etonogestrel—Malnutrition—Doxorubicin—thyroid cancer	0.001	0.00122	CcSEcCtD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.001	0.00554	CbGpPWpGaD
Etonogestrel—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000995	0.00551	CbGpPWpGaD
Etonogestrel—Flatulence—Doxorubicin—thyroid cancer	0.000987	0.0012	CcSEcCtD
Etonogestrel—Tension—Doxorubicin—thyroid cancer	0.000982	0.0012	CcSEcCtD
Etonogestrel—Malaise—Epirubicin—thyroid cancer	0.000976	0.00119	CcSEcCtD
Etonogestrel—Nervousness—Doxorubicin—thyroid cancer	0.000972	0.00119	CcSEcCtD
Etonogestrel—ESR1—Generic Transcription Pathway—THRB—thyroid cancer	0.000969	0.00537	CbGpPWpGaD
Etonogestrel—Back pain—Doxorubicin—thyroid cancer	0.000968	0.00118	CcSEcCtD
Etonogestrel—Muscle spasms—Doxorubicin—thyroid cancer	0.000963	0.00117	CcSEcCtD
Etonogestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000952	0.00527	CbGpPWpGaD
Etonogestrel—ESR1—ATF-2 transcription factor network—CCND1—thyroid cancer	0.000952	0.00527	CbGpPWpGaD
Etonogestrel—Cough—Epirubicin—thyroid cancer	0.000944	0.00115	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—KRAS—thyroid cancer	0.000944	0.00523	CbGpPWpGaD
Etonogestrel—Convulsion—Epirubicin—thyroid cancer	0.000938	0.00114	CcSEcCtD
Etonogestrel—Hypertension—Epirubicin—thyroid cancer	0.000934	0.00114	CcSEcCtD
Etonogestrel—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000929	0.00113	CcSEcCtD
Etonogestrel—Arthralgia—Epirubicin—thyroid cancer	0.000921	0.00112	CcSEcCtD
Etonogestrel—Myalgia—Epirubicin—thyroid cancer	0.000921	0.00112	CcSEcCtD
Etonogestrel—Anxiety—Epirubicin—thyroid cancer	0.000918	0.00112	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000915	0.00112	CcSEcCtD
Etonogestrel—Discomfort—Epirubicin—thyroid cancer	0.00091	0.00111	CcSEcCtD
Etonogestrel—Malaise—Doxorubicin—thyroid cancer	0.000903	0.0011	CcSEcCtD
Etonogestrel—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—thyroid cancer	0.000892	0.00494	CbGpPWpGaD
Etonogestrel—Oedema—Epirubicin—thyroid cancer	0.000883	0.00108	CcSEcCtD
Etonogestrel—Anaphylactic shock—Epirubicin—thyroid cancer	0.000883	0.00108	CcSEcCtD
Etonogestrel—Infection—Epirubicin—thyroid cancer	0.000877	0.00107	CcSEcCtD
Etonogestrel—Cough—Doxorubicin—thyroid cancer	0.000874	0.00107	CcSEcCtD
Etonogestrel—Convulsion—Doxorubicin—thyroid cancer	0.000867	0.00106	CcSEcCtD
Etonogestrel—Nervous system disorder—Epirubicin—thyroid cancer	0.000866	0.00106	CcSEcCtD
Etonogestrel—Hypertension—Doxorubicin—thyroid cancer	0.000864	0.00105	CcSEcCtD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000861	0.00477	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—NRG1—thyroid cancer	0.00086	0.00477	CbGpPWpGaD
Etonogestrel—Skin disorder—Epirubicin—thyroid cancer	0.000858	0.00105	CcSEcCtD
Etonogestrel—Myalgia—Doxorubicin—thyroid cancer	0.000852	0.00104	CcSEcCtD
Etonogestrel—Arthralgia—Doxorubicin—thyroid cancer	0.000852	0.00104	CcSEcCtD
Etonogestrel—Anxiety—Doxorubicin—thyroid cancer	0.000849	0.00104	CcSEcCtD
Etonogestrel—ESR1—Regulation of Telomerase—CCND1—thyroid cancer	0.000849	0.00471	CbGpPWpGaD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000847	0.00103	CcSEcCtD
Etonogestrel—Discomfort—Doxorubicin—thyroid cancer	0.000842	0.00103	CcSEcCtD
Etonogestrel—Anorexia—Epirubicin—thyroid cancer	0.000842	0.00103	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—CCND1—thyroid cancer	0.00083	0.0046	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000828	0.00459	CbGpPWpGaD
Etonogestrel—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000817	0.000997	CcSEcCtD
Etonogestrel—Oedema—Doxorubicin—thyroid cancer	0.000817	0.000997	CcSEcCtD
Etonogestrel—Infection—Doxorubicin—thyroid cancer	0.000812	0.000991	CcSEcCtD
Etonogestrel—ESR1—LKB1 signaling events—TP53—thyroid cancer	0.000807	0.00447	CbGpPWpGaD
Etonogestrel—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000805	0.000982	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—HRAS—thyroid cancer	0.000802	0.00444	CbGpPWpGaD
Etonogestrel—Nervous system disorder—Doxorubicin—thyroid cancer	0.000801	0.000978	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000801	0.00444	CbGpPWpGaD
Etonogestrel—Insomnia—Epirubicin—thyroid cancer	0.000799	0.000975	CcSEcCtD
Etonogestrel—PGR—Gene Expression—THRB—thyroid cancer	0.000795	0.0044	CbGpPWpGaD
Etonogestrel—Skin disorder—Doxorubicin—thyroid cancer	0.000794	0.000968	CcSEcCtD
Etonogestrel—Paraesthesia—Epirubicin—thyroid cancer	0.000793	0.000968	CcSEcCtD
Etonogestrel—ESR1—Leptin signaling pathway—CCND1—thyroid cancer	0.000785	0.00435	CbGpPWpGaD
Etonogestrel—Somnolence—Epirubicin—thyroid cancer	0.000785	0.000958	CcSEcCtD
Etonogestrel—Anorexia—Doxorubicin—thyroid cancer	0.000779	0.00095	CcSEcCtD
Etonogestrel—Dyspepsia—Epirubicin—thyroid cancer	0.000777	0.000949	CcSEcCtD
Etonogestrel—Decreased appetite—Epirubicin—thyroid cancer	0.000768	0.000937	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000762	0.00093	CcSEcCtD
Etonogestrel—Fatigue—Epirubicin—thyroid cancer	0.000761	0.000929	CcSEcCtD
Etonogestrel—Pain—Epirubicin—thyroid cancer	0.000755	0.000921	CcSEcCtD
Etonogestrel—Constipation—Epirubicin—thyroid cancer	0.000755	0.000921	CcSEcCtD
Etonogestrel—PGR—Signaling Pathways—CALCB—thyroid cancer	0.000754	0.00418	CbGpPWpGaD
Etonogestrel—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000744	0.000908	CcSEcCtD
Etonogestrel—Insomnia—Doxorubicin—thyroid cancer	0.000739	0.000902	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—PTEN—thyroid cancer	0.000734	0.00407	CbGpPWpGaD
Etonogestrel—Paraesthesia—Doxorubicin—thyroid cancer	0.000734	0.000895	CcSEcCtD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000731	0.00405	CbGpPWpGaD
Etonogestrel—Feeling abnormal—Epirubicin—thyroid cancer	0.000728	0.000888	CcSEcCtD
Etonogestrel—Somnolence—Doxorubicin—thyroid cancer	0.000726	0.000886	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000722	0.000881	CcSEcCtD
Etonogestrel—Dyspepsia—Doxorubicin—thyroid cancer	0.000719	0.000878	CcSEcCtD
Etonogestrel—PGR—Signaling Pathways—TRIM33—thyroid cancer	0.000715	0.00396	CbGpPWpGaD
Etonogestrel—Decreased appetite—Doxorubicin—thyroid cancer	0.00071	0.000867	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—AKT1—thyroid cancer	0.000708	0.00392	CbGpPWpGaD
Etonogestrel—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000705	0.000861	CcSEcCtD
Etonogestrel—Fatigue—Doxorubicin—thyroid cancer	0.000704	0.00086	CcSEcCtD
Etonogestrel—Urticaria—Epirubicin—thyroid cancer	0.000702	0.000856	CcSEcCtD
Etonogestrel—PGR—Generic Transcription Pathway—RXRA—thyroid cancer	0.000701	0.00388	CbGpPWpGaD
Etonogestrel—Pain—Doxorubicin—thyroid cancer	0.000699	0.000853	CcSEcCtD
Etonogestrel—Constipation—Doxorubicin—thyroid cancer	0.000699	0.000853	CcSEcCtD
Etonogestrel—Body temperature increased—Epirubicin—thyroid cancer	0.000698	0.000852	CcSEcCtD
Etonogestrel—Abdominal pain—Epirubicin—thyroid cancer	0.000698	0.000852	CcSEcCtD
Etonogestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000682	0.00378	CbGpPWpGaD
Etonogestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000678	0.00376	CbGpPWpGaD
Etonogestrel—Feeling abnormal—Doxorubicin—thyroid cancer	0.000673	0.000822	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000668	0.000815	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—NRAS—thyroid cancer	0.000655	0.00363	CbGpPWpGaD
Etonogestrel—Hypersensitivity—Epirubicin—thyroid cancer	0.000651	0.000794	CcSEcCtD
Etonogestrel—Urticaria—Doxorubicin—thyroid cancer	0.000649	0.000792	CcSEcCtD
Etonogestrel—Body temperature increased—Doxorubicin—thyroid cancer	0.000646	0.000788	CcSEcCtD
Etonogestrel—Abdominal pain—Doxorubicin—thyroid cancer	0.000646	0.000788	CcSEcCtD
Etonogestrel—ESR1—Gene Expression—TRIM33—thyroid cancer	0.000645	0.00357	CbGpPWpGaD
Etonogestrel—Asthenia—Epirubicin—thyroid cancer	0.000634	0.000773	CcSEcCtD
Etonogestrel—Pruritus—Epirubicin—thyroid cancer	0.000625	0.000762	CcSEcCtD
Etonogestrel—ESR1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000615	0.00341	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000615	0.00341	CbGpPWpGaD
Etonogestrel—Diarrhoea—Epirubicin—thyroid cancer	0.000604	0.000737	CcSEcCtD
Etonogestrel—Hypersensitivity—Doxorubicin—thyroid cancer	0.000602	0.000735	CcSEcCtD
Etonogestrel—Asthenia—Doxorubicin—thyroid cancer	0.000586	0.000715	CcSEcCtD
Etonogestrel—Dizziness—Epirubicin—thyroid cancer	0.000584	0.000713	CcSEcCtD
Etonogestrel—Pruritus—Doxorubicin—thyroid cancer	0.000578	0.000705	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—KRAS—thyroid cancer	0.000564	0.00312	CbGpPWpGaD
Etonogestrel—Vomiting—Epirubicin—thyroid cancer	0.000561	0.000685	CcSEcCtD
Etonogestrel—Diarrhoea—Doxorubicin—thyroid cancer	0.000559	0.000682	CcSEcCtD
Etonogestrel—Rash—Epirubicin—thyroid cancer	0.000557	0.000679	CcSEcCtD
Etonogestrel—Dermatitis—Epirubicin—thyroid cancer	0.000556	0.000679	CcSEcCtD
Etonogestrel—Headache—Epirubicin—thyroid cancer	0.000553	0.000675	CcSEcCtD
Etonogestrel—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000553	0.00306	CbGpPWpGaD
Etonogestrel—ESR1—AP-1 transcription factor network—TP53—thyroid cancer	0.000547	0.00303	CbGpPWpGaD
Etonogestrel—Dizziness—Doxorubicin—thyroid cancer	0.00054	0.000659	CcSEcCtD
Etonogestrel—PGR—Gene Expression—TPR—thyroid cancer	0.000537	0.00297	CbGpPWpGaD
Etonogestrel—Nausea—Epirubicin—thyroid cancer	0.000525	0.00064	CcSEcCtD
Etonogestrel—Vomiting—Doxorubicin—thyroid cancer	0.00052	0.000634	CcSEcCtD
Etonogestrel—Rash—Doxorubicin—thyroid cancer	0.000515	0.000629	CcSEcCtD
Etonogestrel—Dermatitis—Doxorubicin—thyroid cancer	0.000515	0.000628	CcSEcCtD
Etonogestrel—Headache—Doxorubicin—thyroid cancer	0.000512	0.000625	CcSEcCtD
Etonogestrel—PGR—Gene Expression—MEN1—thyroid cancer	0.000505	0.0028	CbGpPWpGaD
Etonogestrel—ESR1—Leptin signaling pathway—HRAS—thyroid cancer	0.000495	0.00274	CbGpPWpGaD
Etonogestrel—Nausea—Doxorubicin—thyroid cancer	0.000485	0.000592	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—HRAS—thyroid cancer	0.000479	0.00265	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TCF7L1—thyroid cancer	0.000477	0.00264	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of Telomerase—AKT1—thyroid cancer	0.000472	0.00262	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—THRB—thyroid cancer	0.000466	0.00258	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000449	0.00249	CbGpPWpGaD
Etonogestrel—PGR—Generic Transcription Pathway—PPARG—thyroid cancer	0.000443	0.00245	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CALCB—thyroid cancer	0.000442	0.00245	CbGpPWpGaD
Etonogestrel—ESR1—Leptin signaling pathway—AKT1—thyroid cancer	0.000437	0.00242	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000433	0.0024	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—PTEN—thyroid cancer	0.000431	0.00239	CbGpPWpGaD
Etonogestrel—PGR—Signaling by ERBB4—AKT1—thyroid cancer	0.000423	0.00234	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TRIM33—thyroid cancer	0.000419	0.00232	CbGpPWpGaD
Etonogestrel—ESR1—Generic Transcription Pathway—RXRA—thyroid cancer	0.000411	0.00228	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000411	0.00228	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000411	0.00228	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—NRAS—thyroid cancer	0.000384	0.00213	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000372	0.00206	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000359	0.00199	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TSHR—thyroid cancer	0.000349	0.00193	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000343	0.0019	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—RXRA—thyroid cancer	0.000338	0.00187	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000333	0.00184	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—KRAS—thyroid cancer	0.000331	0.00183	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MEN1—thyroid cancer	0.000328	0.00182	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—TPR—thyroid cancer	0.000315	0.00175	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PTCH1—thyroid cancer	0.000297	0.00164	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—MEN1—thyroid cancer	0.000296	0.00164	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000296	0.00164	CbGpPWpGaD
Etonogestrel—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000294	0.00163	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—HRAS—thyroid cancer	0.000281	0.00156	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TCF7L1—thyroid cancer	0.00028	0.00155	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000276	0.00153	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—SST—thyroid cancer	0.000271	0.0015	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CALCA—thyroid cancer	0.000261	0.00145	CbGpPWpGaD
Etonogestrel—ESR1—Generic Transcription Pathway—PPARG—thyroid cancer	0.00026	0.00144	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.00025	0.00138	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—AKT1—thyroid cancer	0.000248	0.00138	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000245	0.00136	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CDK1—thyroid cancer	0.000236	0.00131	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000216	0.0012	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—PPARG—thyroid cancer	0.000213	0.00118	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000207	0.00115	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TSHR—thyroid cancer	0.000205	0.00113	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000201	0.00112	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—RXRA—thyroid cancer	0.000198	0.0011	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MEN1—thyroid cancer	0.000193	0.00107	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—NRG1—thyroid cancer	0.00019	0.00105	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000183	0.00102	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PTCH1—thyroid cancer	0.000174	0.000965	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000172	0.000956	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TERT—thyroid cancer	0.00017	0.000944	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—HIF1A—thyroid cancer	0.000163	0.000903	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SST—thyroid cancer	0.000159	0.000883	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CALCA—thyroid cancer	0.000153	0.00085	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HPGD—thyroid cancer	0.000139	0.00077	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CDK1—thyroid cancer	0.000139	0.000769	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—BRAF—thyroid cancer	0.000135	0.000748	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—PPARG—thyroid cancer	0.000125	0.000693	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NRG1—thyroid cancer	0.000111	0.000617	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TERT—thyroid cancer	0.0001	0.000554	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CCND1—thyroid cancer	9.85e-05	0.000546	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HIF1A—thyroid cancer	9.57e-05	0.00053	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PTEN—thyroid cancer	9.51e-05	0.000527	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—NRAS—thyroid cancer	8.48e-05	0.00047	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—AKT1—thyroid cancer	8.43e-05	0.000467	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TPR—thyroid cancer	7.98e-05	0.000442	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—BRAF—thyroid cancer	7.92e-05	0.000439	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	7.85e-05	0.000435	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—KRAS—thyroid cancer	7.3e-05	0.000404	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TP53—thyroid cancer	6.49e-05	0.00036	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—HRAS—thyroid cancer	6.21e-05	0.000344	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC5A5—thyroid cancer	5.98e-05	0.000331	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CCND1—thyroid cancer	5.78e-05	0.00032	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PTEN—thyroid cancer	5.58e-05	0.000309	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—AKT1—thyroid cancer	5.48e-05	0.000304	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—RXRA—thyroid cancer	5.02e-05	0.000278	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NRAS—thyroid cancer	4.98e-05	0.000276	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—AKT1—thyroid cancer	4.95e-05	0.000274	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—KRAS—thyroid cancer	4.28e-05	0.000237	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TP53—thyroid cancer	3.81e-05	0.000211	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HRAS—thyroid cancer	3.64e-05	0.000202	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—AKT1—thyroid cancer	3.22e-05	0.000178	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PPARG—thyroid cancer	3.17e-05	0.000176	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.49e-05	0.000138	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTEN—thyroid cancer	2.18e-05	0.000121	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—AKT1—thyroid cancer	1.25e-05	6.95e-05	CbGpPWpGaD
